Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Saracatinib in Castrate Resistant Prostate Cancer
NCT01267266Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Dec 2010
- Primary completion
- Sep 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of saracatinib in prostate cancer (PCa), sponsored by National Cancer Institute. Started Dec 2010; status: terminated.
02
Drugs
saracatinib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT01267266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01267266.